IP Library Granted Patent US 9,260,401
Granted Patent B2
US 9,260,401 · App. 14/647,147 · Granted Feb 16, 2016

Method for preparing cabazitaxel from 10-deacetylbaccatin III in high yield, and novel intermediate therefor

Inventors: Na Young Lee (Daejeon, KR); Seong Ho Kim (Daejeon, KR); Young Min Kim (Daejeon, KR); Jin Suk Cho (Daejeon, KR); Moon Suk Kim (Daejeon, KR)
Assignee: SAMYANG BIOPHARMACEUTICALS CORPORATION
C07D305/14A61K31/337C07D413/12C07F7/1844C07F7/1856
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,260,401
App. No.
14/647,147
Granted
Feb 16, 2016
Kind
B2
Abstract

The present invention relates to a novel method for preparing cabazitaxel from 10-deacetylbaccatin III, and a novel intermediate therefor, and more specifically, to: a method which allows cabazitaxel to be more easily prepared in a high yield and in a high purity within a short time compared with a conventional method by preparing cabazitaxel via a novel intermediate using 10-deacetylbaccatin III as a starting material, and thus is suitable for industrial mass production; and a novel intermediate therefor.

Claims (30)

1. A method for preparing cabazitaxel comprising the steps of:

1) reacting 10-deacetylbaccatin III of Chemical Formula 2 with a silylating agent to obtain an intermediate of Chemical Formula 3 in which hydroxy group at the 7 position is protected by a silylated radical;

2) methylating hydroxy group at the 10 position of the intermediate of Chemical Formula 3 to obtain an intermediate of Chemical Formula 4;

3) deprotecting hydroxy group at the 7 position of the intermediate of Chemical Formula 4 to obtain an intermediate of Chemical Formula 5;

4) methylating hydroxy group at the 7 position of the intermediate of Chemical Formula 5 to obtain an intermediate of Chemical Formula 6;

5) esterifying hydroxy group at the 13 position of the intermediate of Chemical Formula 6 in the presence of oxazolidine acid derivative of Chemical Formula 8 to obtain an intermediate of Chemical Formula 7; and

6) treating the intermediate of Chemical Formula 7 with an acid to obtain cabazitaxel of Chemical Formula 1:

wherein

Ac represents acetyl group;

Me represents methyl group;

Ph represents phenyl group; and

M represents a silylated radical.

2. The method for preparing cabazitaxel according to claim 1 , wherein the silylating agent is selected from the group consisting of trialkyl silylating agent, dialkylaryl silylating agent, alkyldiaryl silylating agent, triaryl silylating agent and a combination thereof,

wherein alkyl is C 1 -C 4 linear or branched chain alkyl, and aryl is C 6 -C 10 aryl.

3. The method for preparing cabazitaxel according to claim 1 , wherein the silylating agent is selected from the group consisting of chlorotriethylsilane, t-butyldimethylsilyl chloride, t-butylchlorodiphenylsilane and a combination thereof.

4. The method for preparing cabazitaxel according to claim 1 , wherein the silylation reaction is carried out in polar or nonpolar organic solvent in the presence of a base.

5. The method for preparing cabazitaxel according to claim 4 , wherein the polar organic solvent is selected from the group consisting of C 1 -C 5 alcohol, acetonitrile, dimethyl sulfoxide, dimethylformamide, acetone, tetrahydrofuran, 1,4-dioxane and a combination thereof, and the nonpolar organic solvent is selected from the group consisting of diethyl ether, toluene, benzene, hexane, dichloromethane, ethyl acetate, chloroform and a combination thereof.

6. The method for preparing cabazitaxel according to claim 4 , wherein the base is selected from the group consisting of pyridine, pyrimidine, triethylamine, diethylamine, isopropylamine, N,N-dimethylaminopyridine, diisopropylamine, diisopropylethylamine and a combination thereof.

7. The method for preparing cabazitaxel according to claim 1 , wherein the methylation of hydroxy group is carried out by the use of one or more methylating agents selected from the group consisting of dimethyl sulfate, methyl iodide and trimethyloxonium tetrafluoroborate.

8. The method for preparing cabazitaxel according to claim 1 , wherein the deprotection reaction of hydroxy group is carried out by the use of acid, or a mixture of acid and organic solvent.

9. The method for preparing cabazitaxel according to claim 8 , wherein the acid is selected from the group consisting of hydrohalic acid, sulfuric acid, nitric acid, phosphoric acid, sulfamic acid, perchloric acid, chromic acid, sulfurous acid, nitrous acid, halogenated acid, formic acid, acetic acid, oxalacetic acid, propionic acid, oxalic acid, glycolic acid, tartaric acid, citric acid, fumaric acid, malic acid, succinic acid, butyric acid, trifluoroacetic acid and a combination thereof.

10. The method for preparing cabazitaxel according to claim 8 , wherein the organic solvent is C 1 -C 4 linear or branched chain alcohol.

11. The method for preparing cabazitaxel according to claim 1 , wherein the intermediates of each step in steps (1) to (5) are obtained by a crystallization method and used in the next step without separate purification.

12. The method for preparing cabazitaxel according to claim 1 , which further comprises one or more steps of purifying a material obtained in each step.

13. A compound of Chemical Formula 4:

wherein

Ac represents acetyl group;

Me represents methyl group; and

M represents a silylated radical.

14. The compound according to claim 13 , wherein M is trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl or triarylsilyl, wherein alkyl is C 1 -C 4 linear or branched chain alkyl, and aryl is C 6 -C 10 aryl.

Assignments (2)
MERGER Recorded Nov 3, 2021
From: SAMYANG BIOPHARMACEUTICALS CORPORATION
To: SAMYANG HOLDINGS CORPORATION
Reel/Frame 058013/0766 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2015
From: LEE, NA YOUNG; KIM, SEONG HO; KIM, YOUNG MIN; CHO, JIN SUK; KIM, MOON SUK
To: SAMYANG BIOPHARMACEUTICALS CORPORATION
Reel/Frame 035709/0761 →
Priority Claims (1)
KR 10-2012-0139485 · Dec 4, 2012 · national
Continuity (1)
Related Publication 20150291545A1 · Oct 15, 2015